NLRP3 and metabolic dysfunction-associated steatotic liver disease: Our results would indicate the potentiation by TNFα of the harmful effects elicited by not yet clarified “inflammatory” factors circulating in the plasma of NAFLD patients, a mechanism that was counteracted by the NLRP3 inflammasome inhibition.